Delayed erythropoiesis and pure red cell aplasia (PRCA) have been reported after major ABO-incompatible BMT. We attempted to find risk factors for the development of PRCA in 27 patients who underwent major ABO-incompatible BMT. In all patients, the donor marrow was depleted of RBCs before infusion. In 22 patients, isoagglutinins were determined until they disappeared. In eight (29.6%) out of 27 patients, bone marrow examination following BMT showed the findings of PRCA. We analyzed various clinico-pathologic risk factors and isoagglutinin type was the only significant risk factor. Patients with anti-A isoagglutinins against donor RBC developed PRCA more frequently than patients with anti-B (8/17 vs 0/9). Median days to the disappearance of isoagglutinins tended to be longer in patients with PRCA (PRCA vs non-PRCA, 200 vs 66 days) and in cases with anti-A isoagglutinins (anti-A vs anti-B, 160 vs 51 days). Times to disappearance of isoagglutinins correlated with times to reticulocytes over 1% and initial appearance of donor type RBC (R 2 = 0.708 and 0.711). In conclusion, RBC engraftment following major ABO-incompatible BMT was dependent on the disappearance of isoagglutinins against donor RBC, and anti-A isoagglutinin was a risk factor for the development of PRCA after major ABO-incompatible allogeneic BMT. Bone Marrow Transplantation (2000) 25, 179-184. Keywords: anti-A isoagglutinin; PRCA; ABO-incompatible BMT Major donor-recipient ABO incompatibility is not considered to be a contraindication to successful bone marrow transplantation (BMT). Acute hemolysis by anti-A or anti-B isoagglutinins of recipient origin at the time of donor marrow infusion can effectively be prevented by the removal of anti-A or anti-B isoagglutinins from the recipients or by the depletion of red blood cells from marrow grafts.
= 0.708 and 0.711). In conclusion, RBC engraftment following major ABO-incompatible BMT was dependent on the disappearance of isoagglutinins against donor RBC, and anti-A isoagglutinin was a risk factor for the development of PRCA after major ABO-incompatible allogeneic BMT. Bone Marrow Transplantation (2000) 25, 179-184. Keywords: anti-A isoagglutinin; PRCA; ABO-incompatible BMT Major donor-recipient ABO incompatibility is not considered to be a contraindication to successful bone marrow transplantation (BMT). Acute hemolysis by anti-A or anti-B isoagglutinins of recipient origin at the time of donor marrow infusion can effectively be prevented by the removal of anti-A or anti-B isoagglutinins from the recipients or by the depletion of red blood cells from marrow grafts. [1] [2] [3] [4] Previous studies showed no significant effect of major ABO mismatch on the incidence of graft rejection, the incidence of graft- versus-host disease (GVHD) or survival. 5, 6 However, several reports have described delayed hemolytic anemia, delayed onset of erythropoiesis and pure red cell aplasia (PRCA) after major ABO-incompatible allogeneic BMT. [7] [8] [9] [10] [11] We made an attempt to identify risk factors for the development of PRCA in patients who received a major ABO-incompatible bone marrow graft.
Patients and methods

Patients
One hundred and five adult patients underwent allogeneic BMT at Asan Medical Center from December 1993 to June 1999. Among those, 49 patients (46.7%) received ABOincompatible bone marrow grafts: 15 (14.3%) with a major difference, 17 (16.2%) with a major and a minor difference, and 17 (16.2%) with a minor difference. Among 32 patients who underwent major or major and minor ABO-incompatible BMT, five were not analyzed for the following reasons: early death in three, generalized engraftment failure in one and inadequate data in one. The remaining 27 patients were transplanted for acute myelogenous leukemia (AML) (n = 13), acute lymphoblastic leukemia (ALL) (n = 3), chronic myelogenous leukemia (CML) (n = 4), myelodysplastic syndrome (MDS) (n = 3), idiopathic myelofibrosis (n = 1), non-Hodgkin's lymphoma (NHL) (n = 1), and severe aplastic anemia (SAA) (n = 2). Twenty-two donors were HLA-identical siblings, one was one-locus mismatched sibling, and four were HLA-matched unrelated volunteers.
BMT procedure
Conditioning regimens were BuCy (busulfan 16 mg/kg and cyclophosphamide 120 mg/kg) for patients with leukemia/MDS/NHL and Cy-ATG (cyclophosphamide 200 mg/kg and antithymocyte globulin 90 mg/kg) for SAA. All patients received cyclosporine and methotrexate for the prophylaxis of graft-versus-host disease (GVHD). Cyclosporine was given starting on day −1 and methotrexate was administered on days 1, 3, 6 and 11. Heparin was administered to those patients who received the BuCy regimen for the prevention of hepatic veno-occlusive disease (VOD). In all patients, the donor marrow was depleted of red blood cells by the CS-3000 collection device before infusion. Recipients' isoagglutinins were not reduced before BMT. 
Laboratory evaluation
Complete blood counts including reticulocyte counts were measured daily until discharge from the hospital and were subsequently measured per visit (once per 1 or 2 weeks according to the patients' status). Bone marrow biopsy and aspiration was performed when neutrophil engraftment was established, then usually performed at 3, 6 and 9 months post transplant. PRCA was diagnosed when reticulocytopenia (reticulocyte count Ͻ1%) persisted over 60 days after BMT and bone marrow biopsy showed isolated depletion of erythroid precursors. In 22 patients, isoagglutinins were determined until they disappeared. Tests for ABO/Rhesus type and IgM isoagglutinin titers were performed using standard blood banking procedures. Anti-A and anti-B isoagglutinin titers were determined by incubating a standard type A and B RBC suspension in saline with two-fold serial dilutions of patient serum at room temperature followed by centrifugation and scoring for agglutination. Isoagglutinin titers were measured until disappearance of isoagglutinins against donor RBC.
Statistical analysis
The day of RBC engraftment was defined in two ways: the last day of RBC transfusion when the patients were RBC transfusion independent for у1 month and the first day of three consecutive tests showing reticulocyte counts equal to or more than 1.0%. The day of neutrophil engraftment was defined as the first of 2 consecutive days with an absolute neutrophil count (ANC) Ͼ500/l following the posttransplant nadir. The day of platelet engraftment was defined as the first of 7 consecutive days with a platelet count Ͼ20 000/l without platelet transfusion.
Categorical values were expressed as frequency and percentages. Nonparametric variables were expressed as 181 Table 3 Effect of PRCA on clinical outcomes after BMT median values and ranges. Differences in categorical variables between patients with or without PRCA were tested using the chi-square test, whereas nonparametric data were compared using the Mann-Whitney U test. Statistical analysis of risk factors for PRCA was univariate in each case. The probabilities of engraftment, appearance of donor-type RBC, and disappearance of isoagglutinins against donor RBC were calculated using the KaplanMeier method and compared by log-rank analysis. Pearson's correlation coefficients were computed using the bivariate correlation procedure to measure how variables are related. (Figure 1a) . The titer increased subsequently and persisted at a relatively high level for several months until day 455 post transplant when the titer became undetectable. Patient UPN 39 had no detectable donor RBC until day 77 post transplant. Isoagglutinins against donor RBC were still detected at that time. The changes of isoagglutinins in patient UPN 50 were similar to patient UPN 36 (Figure 1b) . On day 31 post transplant, bone marrow biopsy showed isolated depletion of erythroid precursors, whereas active trilineage regeneration was noted in the bone marrow biopsy of day 282. In patient UPN 61, the isoagglutinin titer decreased over 4 months after BMT and donor RBC appeared on day 125 post transplant. In patients UPN 98 and 102, reticulocytopenia persisted until days 108 and 80, respectively and anti-A isoagglutinins were still detected at those times.
Results
Occurrence of PRCA following major ABO-incompatible BMT
There was no correlation between cyclosporine administration and recovery of erythropoiesis. In five of eight PRCA patients, donor-type red cells appeared while cyclosporine was still being administered (Table 1) .
Risk factors for PRCA
In an attempt to identify risk factors for the development of PRCA, we analyzed various variables such as sex, age, the amount of pre-BMT transfusion, level of AST/ALT at BMT, HBV status, bone marrow cell dose, isoagglutinin type against donor RBC, and pre-BMT isoagglutinin titers (Table 2) . Isoagglutinin type was the only risk factor and patients with anti-A isoagglutinins against donor RBC developed PRCA more frequently than patients with anti-B (8/17 vs 0/9, P = 0.013).
Effect of PRCA on clinical outcomes after BMT
Median days to reticulocytes over 1% were longer by about 3 months in patients with PRCA than in those with timely RBC engraftment (128 vs 26 days, P Ͻ 0.001). Median times to the last day of transfusion when the patients were Bone Marrow Transplantation RBC transfusion independent for у1 month were also delayed in patients with PRCA (129 vs 30 days, P = 0.054).
Those patients who developed PRCA showed a comparable speed of neutrophil and platelet engraftment when compared to the patients who did not develop PRCA. The amounts of platelet and RBC transfusion did not show significant differences according to the occurrence of PRCA. The development of PRCA did not influence the occurrence of GVHD or hepatic VOD, as well as overall survival (Table 3) . 
RBC engraftment kinetics
Times to disappearance of isoagglutinins against donor RBC or appearance of donor RBC were correlated with types of isoagglutinin or the occurrence of PRCA. Median days to the disappearance of isoagglutinins against donor RBC were delayed in patients with anti-A isoagglutinins (anti-A vs anti-B 160 vs 51 days, P = 0.027) or PRCA (PRCA vs non-PRCA 200 vs 66 days, P = 0.006; Figure 2 ). Median days to initial appearance of donor-type RBC were also delayed in patients with anti-A isoagglutinins (anti-A vs anti-B 61 vs 31, P = 0.001) or PRCA (PRCA vs non-PRCA 135 vs 33 days, P Ͻ 0.001; Figure 3 ). Times to disappearance of isoagglutinins against donor RBC were significantly correlated with times to reticulocytes over 1% and initial appearance of donor type RBC (R 2 = 0.708 and 0.711; Figure 4 ).
Discussion
Although a major ABO incompatibility between donors and recipients does not affect the ultimate outcome of allogeneic BMT, it can cause several immediate and delayed complications. The latter include delayed red cell engraftment and PRCA. Post-BMT PRCA occurs in about 20% of the patients who receive a major ABO-incompatible graft, and presents clinically with prolonged reticulocytopenia, selective erythroid hypoplasia, and increased red blood cell transfusion requirements. 7, 8, 10, 12 The probable mechanism of this phenomenon is the presence of recipient isoagglutinins directed at ABH antigens on donor red cells. There are relatively few data regarding ABH antigen expression on human erythroid precursor cells. Sieff et al 13 demonstrated that only a minority of BFU-E were strongly positive (7%) to anti-A antibody, but this proportion increased during differentiation to CFU-E (38%). Sahovic et al 14 studied a major ABO-incompatible BMT recipient with PRCA using flow cytometric analysis of ABH antigen expression by colony cells grown in vitro. They hypothesized that the mechanism of PRCA after ABO-incompatible BMT is complement-mediated immune destruction of erythroid progenitors past the stage of BFU-E in differentiation. Gmür et al 8 reported that RBC engraftment and reticulocyte recovery coincided with the decrease of isoagglutinin titers below 16, and PRCA is antibody-dependent in this setting. Our data also suggested that RBC engraftment was dependent on the disappearance of isoagglutinins against donor RBC.
We attempted to identify risk factors for PRCA after major ABO-incompatible BMT. All eight patients who developed PRCA after BMT had anti-A isoagglutinins against donor RBC and anti-A isoagglutinin was the only risk factor for PRCA. Wernet et al 15 measured isoagglutinins serially following ABO-incompatible BMT and found that it took longer for anti-A to disappear than anti-B. Most cases of PRCA after BMT reported in the literature involve recipients with anti-A isoagglutinins against donor RBC, 8,14,16-18 although a few case reports showed the occurrence of PRCA after BMT when recipients had anti-B isoagglutinins against donor RBC.
19, 20 Bär et al 10 suggested that blood group O was significantly more frequent in the major ABO-incompatible patients with delayed onset of donor erythropoiesis than with timely onset of erythropoiesis. However, the recipient/donor ABO-type of eight PRCA patients in our study was O + /A + in four and B + /A + in four suggesting that anti-A isoagglutinin against donor RBC is more important in the development of PRCA than blood group O. Although we cannot ascertain why anti-A isoagglutinins against donor RBC produced PRCA more frequently, it may be assumed that antibody affinity and expression density of blood group A antigens are higher on RBC precursors than those of blood group B antigens. Some authors reported that delay of RBC engraftment after ABO-incompatible BMT was attributable to high pre-transplant isoagglutinin titers. 1 However, others found no correlation between pretransplant isoagglutinin titers and the development of PRCA. 6, 8, 21 In our patients, pre-BMT isoagglutinin titers did not differ between patients with and without PRCA. Gmür et al 8 observed that a post-transplant rise and persistence of high anti-A agglutinin titers was associated with a delay of RBC engraftment. Bär et al 10 showed that 3 months after major ABO-incompatible BMT, seven patients with PRCA had detectable isoagglutinin titers in a range higher than the other patients without PRCA. Our data also showed that in three (UPN 32, 36, 50) of six patients with PRCA, post-transplant isoagglutinin titers initially decreased with subsequent transient increment and eventual disappearance (Figure 1 ). Several authors suggested that cyclosporine might have a role in the development of PRCA after ABO-incompatible BMT. 8, 22, 23 However, we did not observe a correlation of cyclosporine and erythropoiesis in major ABO-incompatible BMT. It was also suggested that measures taken for the prevention of acute hemolysis by isoagglutinins of recipient origin at the time of donor marrow infusion may influence RBC engraftment after major ABO-incompatible BMT. 3 In all our patients, donor marrow was depleted of red blood cells before infusion and recipients' isoagglutinins were not reduced before BMT. The incidence of PRCA (29.6%) in our study is somewhat higher than the incidence reported previously in the literature. In the study by Gmür et al, 8 timely recovery of erythropoiesis was observed in all seven patients who underwent large volume plasma exchange before BMT, but three of seven patients who received an RBC-depleted graft developed PRCA after major ABOincompatible BMT.
In summary, RBC engraftment following major ABOincompatible BMT was dependent on the disappearance of isoagglutinins against donor RBC, and anti-A isoagglutinin was a risk factor for the development of PRCA complicating major ABO-incompatible BMT.
